Aignostics Unveils Breakthrough Pathology Foundation Model Developed with Mayo Clinic
On January 13, 2025, Aignostics announced groundbreaking results for its newly developed pathology foundation model, a collaboration with the Mayo Clinic Digital Pathology team. This innovative model sets a new industry benchmark thanks to its exceptional performance, evaluated against over twenty public benchmarks. Within just two months, the model was constructed using an impressive dataset comprising 1.2 million diverse slide images sourced from the Mayo Clinic and Charité – Universitätsmedizin Berlin. Moreover, the model’s computational efficiency enhances its practical applicability, allowing it to outperform existing image-based models.
A key aspect of the model's success is the collaborative approach employed by Aignostics. By integrating the expertise of pathologists directly into the model development process, the team was able to ensure a focus on creating genuine medical insights. "These results mark a significant achievement in our collaboration with the Mayo Clinic," stated Maximilian Alber, CTO of Aignostics. The company, along with the Mayo Clinic, has direct access to millions of additional training images and new data modalities that will be progressively integrated into the model to enhance its abilities and accuracy over time.
Healthcare and bioscience organizations stand to benefit greatly from this powerful new tool that facilitates research and clinical development. Aignostics plans to integrate this model into its expanding range of AI-powered pathology products, which will enable accurate and generalizable analysis of biomarkers, cells, and tissue images. This dual approach features both the direct licensing of foundational technology and the provision of tailored applications, empowering partner organizations to utilize the model's capabilities in ways that best meet their specific needs.
Jim Rogers, CEO of Mayo Clinic Digital Pathology, expressed optimism regarding the partnership, stating, "Mayo Clinic Digital Pathology is excited to collaborate with Aignostics to transform pathology for patient benefit across the globe." Viktor Matyas, CEO of Aignostics, emphasized the substantial potential that arises from combining the extensive medical expertise and resources of the Mayo Clinic with Aignostics’ leading-edge technologies. “These results underscore our ambition and readiness to take a leading role in this domain together," he added.
Founded in 2018 as a spin-off from Charité Berlin, one of the largest and most prestigious university hospitals in the world, Aignostics specializes in transforming complex pathology data into actionable insights. The company blends proprietary access to multimodal clinical data with cutting-edge technologies and rigorous scientific methodology to deliver top-tier products and services for the future of precision medicine. Working alongside its biopharmaceutical partners, Aignostics supports drug discovery, translational research, clinical trials, and companion diagnostics development. The company is backed by leading investors and operates offices in Berlin and New York. For further information, visit Aignostics or follow them on LinkedIn.
This significant advancement showcases Aignostics’ commitment to revolutionizing pathology through technology, ultimately benefiting patients and the broader healthcare ecosystem. As they continue to innovate and expand their capabilities, Aignostics is poised to make significant contributions to the field of medical diagnostics, enhancing the accuracy and efficiency of disease detection and treatment planning.
A key aspect of the model's success is the collaborative approach employed by Aignostics. By integrating the expertise of pathologists directly into the model development process, the team was able to ensure a focus on creating genuine medical insights. "These results mark a significant achievement in our collaboration with the Mayo Clinic," stated Maximilian Alber, CTO of Aignostics. The company, along with the Mayo Clinic, has direct access to millions of additional training images and new data modalities that will be progressively integrated into the model to enhance its abilities and accuracy over time.
Healthcare and bioscience organizations stand to benefit greatly from this powerful new tool that facilitates research and clinical development. Aignostics plans to integrate this model into its expanding range of AI-powered pathology products, which will enable accurate and generalizable analysis of biomarkers, cells, and tissue images. This dual approach features both the direct licensing of foundational technology and the provision of tailored applications, empowering partner organizations to utilize the model's capabilities in ways that best meet their specific needs.
Jim Rogers, CEO of Mayo Clinic Digital Pathology, expressed optimism regarding the partnership, stating, "Mayo Clinic Digital Pathology is excited to collaborate with Aignostics to transform pathology for patient benefit across the globe." Viktor Matyas, CEO of Aignostics, emphasized the substantial potential that arises from combining the extensive medical expertise and resources of the Mayo Clinic with Aignostics’ leading-edge technologies. “These results underscore our ambition and readiness to take a leading role in this domain together," he added.
Founded in 2018 as a spin-off from Charité Berlin, one of the largest and most prestigious university hospitals in the world, Aignostics specializes in transforming complex pathology data into actionable insights. The company blends proprietary access to multimodal clinical data with cutting-edge technologies and rigorous scientific methodology to deliver top-tier products and services for the future of precision medicine. Working alongside its biopharmaceutical partners, Aignostics supports drug discovery, translational research, clinical trials, and companion diagnostics development. The company is backed by leading investors and operates offices in Berlin and New York. For further information, visit Aignostics or follow them on LinkedIn.
This significant advancement showcases Aignostics’ commitment to revolutionizing pathology through technology, ultimately benefiting patients and the broader healthcare ecosystem. As they continue to innovate and expand their capabilities, Aignostics is poised to make significant contributions to the field of medical diagnostics, enhancing the accuracy and efficiency of disease detection and treatment planning.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.